Skip to Content
Merck
  • In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes.

In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes.

Nanomedicine : nanotechnology, biology, and medicine (2014-02-04)
Jian Li, Aakansha Pant, Chee Fei Chin, Wee Han Ang, Cécilia Ménard-Moyon, Tapas R Nayak, Dan Gibson, Sundara Ramaprabhu, Tomasz Panczyk, Alberto Bianco, Giorgia Pastorin
ABSTRACT

Carbon nanotubes (CNTs) are promising drug delivery systems due to their external functionalizable surface and their hollowed cavity that can encapsulate several bioactive molecules. In this study, the chemotherapeutic drug cisplatin or an inert platinum(IV) complex were entrapped inside functionalized-multi-walled-CNTs and intravenously injected into mice to investigate the influence of CNTs on the biodistribution of Pt-based molecules. The platinum levels in vital organs suggested that functionalized-CNTs did not affect cisplatin distribution, while they significantly enhanced the accumulation of Pt(IV) sample in some tissues (e.g. in the lungs, suggesting their potential application in lung cancer therapy) and reduced both kidney and liver accumulation (thus decreasing eventual nephrotoxicity, a typical side effect of cisplatin). Concurrently, CNTs did not induce any intrinsic abnormal immune response or inflammation, as confirmed by normal cytokine levels and histological evaluations. Therefore, functionalized nanotubes represent an efficient nano-carrier to improve accumulation of Pt species in targeted tissues/organs. From the clinical editor: In this preclinical study functionalized carbon nanotubes are reported to be safe and efficient for targeted delivery of platinum-containing compounds in rodents. Approaches like this may improve the treatment of specific cancers, since platinum based chemotherapies are commonly used, yet limited by toxicity and relatively poor target tissue concentration.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Formaldehyde-12C solution, 20% in H2O, 99.9 atom % 12C
Sigma-Aldrich
Nitric-14N acid solution, ~10 N in H2O, 99.99 atom % 14N
Sigma-Aldrich
Formaldehyde solution, tested according to Ph. Eur.
Sigma-Aldrich
Formaldehyde solution, for molecular biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
cis-Diamineplatinum(II) dichloride, ≥99.9% trace metals basis
Sigma-Aldrich
Tetramethylammonium hydroxide solution, ACS reagent
Sigma-Aldrich
Tetramethylammonium hydroxide solution, 10 wt. % in H2O
Sigma-Aldrich
Tetramethylammonium hydroxide solution, 25 wt. % in methanol
Sigma-Aldrich
Formaldehyde solution, for molecular biology, 36.5-38% in H2O
Supelco
Formaldehyde solution, stabilized with methanol, ~37 wt. % in H2O, certified reference material
Sigma-Aldrich
Formaldehyde solution, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Sigma-Aldrich
Tetramethylammonium hydroxide solution, 25 wt. % in H2O
Sigma-Aldrich
Formaldehyde solution, meets analytical specification of USP, ≥34.5 wt. %
Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard
SAFC
Formaldehyde solution, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
USP
Transplatin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Nitric acid, ACS reagent, ≥90.0%
Supelco
Nitric acid concentrate, 0.1 M HNO3 in water (0.1N), eluent concentrate for IC
Cisplatin, European Pharmacopoeia (EP) Reference Standard
Supelco
Trimethylphenylammonium hydroxide solution, ~0.5 M (CH3)3N(OH)C6H5 in methanol, for GC derivatization, LiChropur
Sigma-Aldrich
Trimethylphenylammonium hydroxide solution, ~25% in H2O (1.68 M)
Sigma-Aldrich
trans-Platinum(II)diammine dichloride
Sigma-Aldrich
cis-Diammineplatinum(II) dichloride, crystalline
Sigma-Aldrich
Nitric acid, puriss. p.a., 65.0-67.0%
Sigma-Aldrich
Nitric acid, 70%, purified by redistillation, ≥99.999% trace metals basis
Sigma-Aldrich
Nitric acid, ACS reagent, 70%
Sigma-Aldrich
2,2′-(Ethylenedioxy)bis(ethylamine), 98%